2 Information about ixazomib

Marketing authorisation indication

2.1 Ixazomib citrate (Ninlaro, Takeda), in combination with lenalidomide and dexamethasone, is indicated for 'the treatment of adult patients with multiple myeloma who have had at least 1 previous therapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for ixazomib.


2.3 The list price is £6,336 per pack of 3 capsules (excluding VAT; BNF online, accessed November 2022).

2.4 The company has a commercial arrangement. This makes ixazomib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know the details of the discount.

  • National Institute for Health and Care Excellence (NICE)